Surmodics publishes TRANSCEND trial data

Surmodics (SRDX) announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating the SurVeil drug-coated balloon is non-inferior to the IN.Pact Admiral DCB for safety and efficacy in patients with femoropopliteal arterial disease while using a substantially lower drug dose. The findings were published in the March edition of the European Journal of Vascular and Endovascular Surgery.